Q-omics provides the consensus-scored PRIM1 profile across patient tissues and cancer cell-line models. PRIM1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRIM1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, PRIM1 protein abundance shows 23,481 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where PRIM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRIM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRIM1 survival associations across molecular data types. PRIM1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRIM1 RNA expression–survival associations across cancer types. High PRIM1 expression shows unfavorable associations in MESO, ACC, LIHC and KICH, but favorable associations in OV and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PRIM1 RNA expression.
This table summarizes PRIM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRIM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRIM1 shows higher tumor expression in BLCA, HNSC, COAD, KIRC, LIHC and KIRP. The BLCA box plot shows higher PRIM1 RNA expression in tumor versus normal tissue (log2 FC = +1.884, t-test p < 0.001).
This table shows molecular features associated with PRIM1 in patient tissues and cancer cell lines. In patient samples, PRIM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRIM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
